Technical Analysis for RLAY - Relay Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | -3.41% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -7.79% | |
| NR7 | Range Contraction | -7.79% | |
| Narrow Range Bar | Range Contraction | -7.79% | |
| Inside Day | Range Contraction | -7.79% | |
| 50 DMA Resistance | Bearish | -7.53% | |
| Wide Range Bar | Range Expansion | -7.53% | |
| Earnings Movers | Other | -7.53% |
| Alert | Time |
|---|---|
| Down 5% | about 20 hours ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| 20 DMA Support | about 23 hours ago |
| Down 3% | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
Relay Therapeutics, Inc. Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Drug Discovery Enzymes Precision Medicine Tyrosine Kinase Receptors Tyrosine Kinase Advanced Solid Tumors Fibroblast Growth Factor Fibroblast Growth Factor Receptor Metastatic Solid Tumors Proto Oncogene Tyrosine Protein Kinase Src Ptpn11
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.32 |
| 52 Week Low | 5.7 |
| Average Volume | 1,194,322 |
| 200-Day Moving Average | 9.04 |
| 50-Day Moving Average | 7.69 |
| 20-Day Moving Average | 6.55 |
| 10-Day Moving Average | 6.67 |
| Average True Range | 0.53 |
| RSI (14) | 42.20 |
| ADX | 31.8 |
| +DI | 31.21 |
| -DI | 19.46 |
| Chandelier Exit (Long, 3 ATRs) | 7.12 |
| Chandelier Exit (Short, 3 ATRs) | 7.29 |
| Upper Bollinger Bands | 7.34 |
| Lower Bollinger Band | 5.75 |
| Percent B (%b) | 0.48 |
| BandWidth | 24.37 |
| MACD Line | -0.22 |
| MACD Signal Line | -0.35 |
| MACD Histogram | 0.1297 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.96 | ||||
| Resistance 3 (R3) | 6.96 | 6.80 | 6.89 | ||
| Resistance 2 (R2) | 6.80 | 6.69 | 6.81 | 6.86 | |
| Resistance 1 (R1) | 6.66 | 6.62 | 6.58 | 6.66 | 6.83 |
| Pivot Point | 6.50 | 6.50 | 6.47 | 6.51 | 6.50 |
| Support 1 (S1) | 6.36 | 6.39 | 6.28 | 6.36 | 6.19 |
| Support 2 (S2) | 6.20 | 6.32 | 6.21 | 6.16 | |
| Support 3 (S3) | 6.06 | 6.20 | 6.14 | ||
| Support 4 (S4) | 6.06 |
